Abstract. Congenital hyperinsulinism is a rare condition, and following recent advances in diagnosis and treatment, it was considered necessary to formulate evidence-based clinical practice guidelines reflecting the most recent progress, to guide the practice of neonatologists, pediatric endocrinologists, general pediatricians, and pediatric surgeons. These guidelines cover a range of aspects, including general features of congenital hyperinsulinism, diagnostic criteria and tools for diagnosis, first-and second-line medical treatment, criteria for and details of surgical treatment, and future perspectives. These guidelines were generated as a collaborative effort between The Japanese Society for Pediatric Endocrinology and The Japanese Society of Pediatric Surgeons, and followed the official procedures of guideline generation to identify important clinical questions, perform a systematic literature review (April 2016), assess the evidence level of each paper, formulate the guidelines, and obtain public comments.
I Introduction
A Guideline target population 1 Patients < 18 yr with congenital hyperinsulinism (congenital hyperinsulinemic hypoglycemia) a Includes both syndromic and nonsyndromic form (Table 1) 
B Objectives
To improve the following outcomes: 1 Neurological sequelae (developmental delay, epilepsy) 2 Development of postsurgical diabetes mellitus • These guidelines aim to present general principles. Each patient, therefore, may be treated on a case-by-case basis, according to the conditions specific to the patient.
C Intended users 1 General pediatricians and neonatologists 2 Pediatric endocrinologists 3 Pediatric surgeons

D Outline of the disorder
• Congenital hyperinsulinism (CHI) is a group of disorders causing persistent hypoglycemia, due to congenital over-secretion of insulin, and does not include acquired conditions, such as insulinoma, iatrogenic hyperinsulinemia, or dumping syndrome. It is the most common cause of persistent hypoglycemia in neonates and infants, and was previously referred to as "nesidioblastosis" or "persistent hyperinsulinemic hypoglycemia in infancy (PHHI)". However, these terms are not appropriate as "nesidioblastosis" is a histopathological condition that can be observed in normal newborns and patients with CHI can develop hypoglycemia beyond infancy (1, 2).
• There are two forms of CHI: a transient form, which develops soon after birth and generally resolves by 3-4 mo of age, and a persistent form, with a more protracted duration. In some cases, the symptoms of persistent CHI may manifest after infancy. According to the 2009-2010 National Survey in Japan, the incidence of transient CHI is estimated at 1 in 17,000 births and that of persistent CHI at 1 in 35,400 births (3).
• Hypoglycemia may manifest loss of consciousness or convulsions and, most importantly, recurrent or persistent hypoglycemia may result in severe neurological sequelae, such as epilepsy or developmental delay. Optimal control of blood glucose, therefore, is of crucial importance (4, 5).
• Medical treatment for CHI includes nutritional support by hypertonic glucose infusion, continuous feeding through gastrostomy or nasogastric tube, or the use of cornstarch or formula for glycogen storage diseases. Furthermore, oral administration of diazoxide, a pancreatic β cells K ATP channel opener, has been approved for the treatment of CHI. For patients with diazoxide unresponsive CHI, the following therapies have been attempted: off-label use of octreotide, as multiple daily injections or continuous infusion; glucagon, as a continuous infusion; intravenous injection of glucocorticoids; or oral administration of nifedipine (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) ).
• When euglycemia cannot be maintained by medical treatment, pancreatectomy has been performed to avoid neurological sequelae. However, the majority of patients who underwent subtotal pancreatectomy developed postsurgical insulin-dependent diabetes Vol.26 / No.3 mellitus. This is consistent with the study showing that, after 11 yr of operation, diabetes mellitus developed in 96% of 45 patients who underwent > 95% pancreatectomy (17) . A further study reported that, after 14 yr, glucose intolerance and insulin-dependent diabetes mellitus developed in 100% and 91% of 58 patients who underwent subtotal pancreatectomy for the diffuse form of CHI, respectively (18) . In individuals with a paternally-inherited monoallelic mutation in one of the K ATP channel genes, the focal form of CHI can develop as a consequence of the somatic loss of the maternal allele in a developing pancreatic β cell. The focal form of CHI can be diagnosed by mutational analysis and an 18 F-DOPA PET scan (19) (20) (21) (22) (23) (24) . When a focal lesion is successfully resected by partial pancreatectomy, the patient can be cured without postsurgical sequelae. However, the resection should be performed with caution, particularly when the focal lesion is located in the head of the pancreas, as these lesions are in close proximity to the common bile duct and the main pancreatic duct. Resection of the head of the pancreas and distal pancreatojejunostomy using a Roux-en-Y loop have been proposed as treatment for lesions in the head of the pancreas that cannot be enucleated (25) . Mechanisms other than the paternally-inherited monoallelic mutation of the K ATP channel genes cause a diffuse form of CHI. However, atypical cases with scattered patchy clusters of abnormal β cells have been reported (atypical CHI) (26) (27) (28) . Furthermore, reports have described a case of Costello syndrome, with a mutation in the HRAS gene, presenting with a typical focal lesion indistinguishable from that caused by K ATP channel mutations (29, 30) .
• Even in patients with persistent CHI, the severity of hypoglycemia tends to improve over time and patients often achieve spontaneous remission without the need for medical treatment (31) . Diabetes mellitus can develop after medical treatment (32), although the incidence is much lower compared with that observed in patients following subtotal pancreatectomy (5).
II Etiology • Pathophysiology • Diagnosis
A Etiology • Pathophysiology (Table 1) 1 Pathophysiology CHI is a group of disorders that causes persistent hypoglycemia due to congenital over-secretion of insulin. Table 3 , or Fulfills one of the criteria + either identification of the presence of the causes of acquired hyperinsulinemic hypoglycemia in Table 1 , or identification of a mutation in one of the known causative genes. (2) Possible Fulfills one of the criteria in (34) . After 48 h, the threshold for the counter-regulatory reaction against hypoglycemia is the same as that of adults. However, children tend to develop hypoglycemia with blood glucose < 70 mg/ dL due to limited glycogen reserves or the source for gluconeogenesis (33) . After 72 h, the response of glucose stimulated insulin secretion is also the same as that of older children (33) . Physiological transient hypoglycemia after birth is likely to be caused by relative hyperinsulinemia at this stage in life (35) , and the decline could be significant in low birth weight neonates or in preterm neonates, causing transient CHI hypoglycemia.
• By definition, hyperinsulinemic hypoglycemia is hypoglycemia resulting from an over-secretion of insulin. The definition of hypoglycemia, therefore, is a starting point to diagnose hyperinsulinemic hypoglycemia. Considering the physiological fluctuation of blood glucose after birth, hypoglycemia can be defined as blood glucose < 60 mg/dL beyond 48 h after birth (33) or blood glucose < 50 mg/dL for up to 48 h after birth. However, normal blood glucose is affected by a number of factors, including birth weight or gestational age. Therefore, the diagnosis of hypoglycemia could be extended until after 48 h of birth.
• The definition of "over-secretion" of insulin during hypoglycemia is controversial. Some reports have stated that any detectable level of insulin during hypoglycemia is abnormal (6) while others set a higher threshold for insulin levels during hypoglycemia (11, 36) . While measurable insulin levels during hypoglycemia are generally indicative of hyperinsulinemic hypoglycemia, in some cases, patients presenting with measurable insulin levels during hypoglycemia were diagnosed with other hypoglycemic disorders (11) . Insulin levels > 3 μU/mL during hypoglycemia were associated with a sensitivity of 93% and specificity of 95% for the diagnosis of insulinoma (37) . Other proposed indices for the diagnosis of insulinoma include insulin (pmol/L) / (blood glucose (mmol/L)-1.7) > 53.6, with a sensitivity and specificity of 98%; C-peptide (nmol/L) / (blood glucose (mmol/L)-1.7) > 0.61, with a sensitivity of 95% and a specificity of 94%; or insulin / β-hydroxybutyrate < 2.7 mmol/L, with a sensitivity and a specificity of 100% (38) . In cases of congenital hyperinsulinism, it has been suggested that C-peptide > 0.5 ng/mL is a better index than insulin (39) . However, this guideline uses insulin as a diagnostic test, as C-peptide or proinsulin are not routinely measured in hypoglycemia in many emergency care centers. . In cases of adult insulinoma, it was found that BHB < 2.7 mmol/L with a blood glucose < 60 mg/dL has a sensitivity and a specificity of 100% (37) . Van Veen et al. (41) reported BHB levels of 0.91-3.31 mmol/L (mean 2.23) and FFA levels of 1.03-3.24 mmol/L (mean 2.15) in normal infants < 2 yr of age after 20 h of fasting. We therefore set the criteria of BHB and FFA accordingly.
• Conversely, undetectable insulin at hypoglycemia does not necessarily exclude a diagnosis of CHI (36, 42) . Secretion of insulin could be episodic and insulin has a short half-life (2%/min) in the blood. Compared with insulin, C-peptide has a longer half-life and is more suitable for diagnosis although it is not measured routinely in the emergency setting. Glycemic response by the glucagon test is another useful index. Glycemic response > 30 mg/dL during hypoglycemia by the glucagon test strongly suggests the diagnosis of CHI (6, 33, 36, 43 ).
• The glucose infusion rate (GIR) to maintain euglycemia matches the rate of gluconeogenesis at the age of the patient. GIR is 4-6 mg/kg/min in neonates, and 1-2 mg/kg/min in adults. The values applicable to children are in between these values. Patients with CHI could develop symptoms after infancy; therefore, GIR cutoffs of 8-10 mg/kg/min for neonates cannot be applied to older children (6, 11) . We therefore set age specific cutoffs for GIR.
• Laboratory test standardization between centers is insufficient; therefore, it is important to make a diagnosis of hyperinsulinemic hypoglycemia taking the clinical findings into account and not to stick to the cutoffs too rigorously. • To diagnose congenital hyperinsulinism, it is important to exclude acquired causes of hyperinsulinemic hypoglycemia (Table 1) . These include insulin overdose for diabetes, insulinoma, insulin autoimmune syndrome (Hirata disease), noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS), post-gastric bypass, post-fundoplication for gastroesophageal reflux, or dumping syndrome with postprandial hypoglycemia (10).
• Therefore, in addition to meticulous history taking, the following tests and investigations are useful: exogenous insulin, measured by the inconsistent insulin/C-peptide ratio; imaging studies of the pancreas, including CT, MRI, and endoscopic ultrasound; or anti-insulin antibody tests. (Fig. 1) A CQs pertaining to treatment goals and the first line treatment. • There is no evidence-based blood glucose threshold for the prevention of hypoglycemic neurological sequelae (33) . In addition to blood glucose levels, a number of factors affect neurological outcome in hypoglycemia, including patient age; presence or absence of convulsions or loss of consciousness; and co-morbidities, such as infection, fever, hypoxemia, or ischemia (46) . Repeated exposure to mild hypoglycemia, slightly below 45 mg/ dL, could cause significant developmental delay (47) .
III Treatment Goals • First Line Treatment
On the contrary, in normal term-late preterm neonates, maintaining blood glucose above 47 mg/dL was not associated with neurological sequelae at 2 yr of age (48) .
The recommended blood glucose target of > 70 mg/dL has a "margin of safety" such that inability to achieve the target level does not necessarily cause neurological sequelae. (49) . Therefore, the aim should be to achieve blood glucose levels > 70 mg/dL by continuous glucose infusion. Blood glucose < 45 mg/dL should be avoided, even temporarily (47, 48).
• Generally, a central venous catheter is required when continuous glucose infusion above 7 mg/kg/min is necessary.
• Continuous glucose infusion may result in hypoglycemia caused by an incidental infusion problem. Furthermore, administration through a central venous catheter, poses additional risks of septicemia or thrombosis and it would be more difficult to care for the patients at home. Therefore, after stabilization of glycemic control, early transition to enteral nutritional treatment, including frequent feeding, use of cornstarch or formula for glycogen storage diseases, continuous feeding through nasogastric tube or gastrostomy is required (9, 50).
In patients with glycogen storage disease type 1, cornstarch is reported to be more effective in preventing nocturnal hypoglycemia than continuous feeding (51) . The efficacy of cornstarch for severely affected CHI is limited, but is used frequently for patients with CHI after 9-12 mo of age (50, (52) (53) (54) (55) . Similarly, the formula for glycogen storage diseases, especially the night-time formula mostly composed of carbohydrates (GSD-N), (50, (52) (53) (54) (55) is often used for younger infants with CHI. The use of cornstarch and formula for glycogen storage diseases is described in detail in reference (56 (57, 58, 60) . Therefore, care should be taken when administering diazoxide to low birth weight infants, and it is desirable to prescribe diazoxide along with diuretics. As diuretics, thiazides are preferred over loop diuretics (9).
IV Second Line Treatment
A CQs pertaining to second line treatment (Fig. 1 • When the patient is unresponsive to diazoxide, and blood glucose cannot be stabilized by the first line treatment, second line treatment should be initiated promptly to establish stable blood glucose control and avoid long-term hospitalization.
• When the patient is responsive to diazoxide, the treatment should be continued and supplemented by nutritional therapy, if required. If the patient responds well to nutritional therapy, diazoxide can be gradually decreased and eventually withdrawn (CQ10).
• In patients with diazoxide unresponsive CHI whose blood glucose cannot be stabilized by the first line treatment, second line treatments should be initiated without delay (Table 4) . While stabilizing blood glucose levels, mutational analysis and 18 F-DOPA PET scans should be performed to explore the possibility of cure by partial pancreatectomy. Currently, none of the medication for the second line therapy is approved in Japan for this indication.
• 18 F-DOPA PET scans are available only at limited centers at the time of writing these guidelines.
• Octreotide is a long acting somatostatin analog acting through somatostatin receptors 2 and 5 to suppress secretion of insulin from the β cells. Octreotide is the most commonly used second line treatment. Its efficacy for congenital hyperinsulinism has been reported since the 1990s (31, 61, 62 of necrotizing enterocolitis were reported in patients receiving octreotide up to 30 d following birth, although a case involving a child has also been reported (71) . Therefore, the use of octreotide in neonates should be approached with particular care (9) and physicians should be alerted by abdominal symptoms, even beyond infancy. Other problems include attenuating efficacy after extended period of administration (tachyphylaxis) or paradoxical hypoglycemia (72) . Physicians should be aware of these side effects and look for signs of the side effects at each visit.
• Glucagon is counter-regulatory to the effect of insulin and causes elevation of blood glucose by promoting hepatic glycogenolysis and gluconeogenesis. Intramuscular or subcutaneous injection of 0.5-1 mg is commonly used for the treatment of hyperinsulinemic hypoglycemia. In addition, continuous IV infusion of glucagon is often used for the glycemic control of CHI, alone or along with octreotide (31) . There are reports of successful glycemic control of CHI by continuous subcutaneous infusion of glucagon (73, 74) . However, currently available preparations of glucagon tend to precipitate in the infusion tube making long term treatment impractical (9). • Nifedipine is a calcium antagonist, which is thought to act by blocking the influx of calcium into the pancreatic β cells (31) . The efficacy is usually limited but successful glycemic control for residual hypoglycemia after pancreatectomy has been reported (75-77).
• Approximately 90% of patients with diazoxide unresponsive CHI have mutations in the K ATP channel genes, ABCC8 or KCNJ11) (78, 79) . Patients with paternally-inherited monoallelic mutations in the K ATP channel genes may have a focal lesion, potentially amenable to cure by partial pancreatectomy without postsurgical sequelae. Therefore, it is important to identify focal lesions in patients who still require glucose infusion or whose blood glucose cannot be stabilized after the initiation of second line treatment (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 80) . Some patients with a paternally-inherited monoallelic mutation are known to have a diffuse lesion, but the possibility of a focal lesion is at least 50% (9). Furthermore, 84.2% of Japanese patients with K ATP channel mutations were reported to have a paternally-inherited monoallelic mutation (81 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . In patients with inadequate glycemic control by medical treatment, the possibility of surgical treatment should be considered by weighing the risks of postsurgical complication against the risks of hypoglycemic neurological sequelae and the burden of continued medical treatment itself.
• The pooled accuracy of 18 F-DOPA PET scans by metaanalysis has been reported as 82% (22) . Furthermore, according to a standardized protocol for 18 F-DOPA PET/ CT published in 2005, a focal lesion could be accurately localized (sensitivity 94%, specificity 100%) (84) . It is hypothesized that the specificity of 18 F-DOPA PET scan is very high for a focal lesion in the body and the tail, where artifact uptake usually does not pose difficulties.
• For a focal lesion in the body and the tail, the risk of damage to the main pancreatic duct or the bile duct is low. Even when the focal lesion cannot be identified intraoperatively, the patient can be cured by resection of the pancreas distal to the area identified by 18 F-DOPA PET scan.
• On the contrary, for a focal lesion in the head of the pancreas, enucleation could be difficult because of the risks of damaging the main pancreatic duct or the bile duct during surgery. Particularly in neonates, damage to the main pancreatic duct can only be known when it is damaged (91) , and leak of pancreatic juice cannot be prevented intraoperatively. For these patients, resection of the head of the pancreas and distal pancreatojejunostomy using the Roux-en-Y loop is recommended (25) . Since the surgical stress associated with this operation is considerable, a therapeutic strategy should be planned, carefully weighing the risks of the surgery against the risks of continued medical treatment until spontaneous remission (92) by a multidisciplinary team including pediatric surgeons.
• There have been reports of laparoscopic pancreatectomy for CHI (93) (94) (95) (96) . Although the evidence is limited, laparoscopic pancreatectomy can be considered in experienced centers. shown in the NOTE in CQ7.
• Even after > 95% pancreatectomy, residual hypoglycemia is commonly observed. The incidence of postsurgical insulin dependent diabetes mellitus is also high and euglycemia is achieved in only the minority of the patients (17, 18, 91) . In a report by Beltrand et al. (18) , out of 105 patients who underwent subtotal pancreatectomy, hypoglycemia remained in 59%, hyperglycemia immediately after surgery in 53%, hyperglycemia after 13 years in 100%, and insulin dependent diabetes mellitus after 14 yr in 91%. Similarly, Arya et al. (17) reported the incidence of diabetes mellitus after 11 years as 96% among 45 patients who underwent 95% pancreatectomy.
• Hypoglycemia in CHI tends to reach remission with age, and often patients reach complete remission after a long period of medical treatment (54, 63, 97) . Post treatment diabetes mellitus is reported in patients who were treated by medical treatment alone. The incidence of diabetes, however, is much higher in patients who underwent pancreatectomy (98) . Furthermore, it has been reported that neurological prognosis did not differ between patients who underwent pancreatectomy and those treated only by medical treatment (5, 99).
• Some investigators recommend performing 50-75% pancreatectomy for patients whose glycemic control is not satisfactory after introduction of the second line treatment to make the medical management easier (9, 91) . No data exist on the risk of future diabetes mellitus as it relates to the extent of pancreatectomy.
V Surgical Treatment (Fig. 1) 1 CQ 7: What is the optimal surgical procedure for a diffuse lesion resistant to medical treatment? • Recommendation • Optimal extent of pancreatectomy for a diffuse lesion has not been established.
[Recommendation level 0, Evidence level C] • NOTES
• By definition, 85% pancreatectomy is a resection of the distal pancreas at the right margin of the superior mesenteric vein; 95% pancreatectomy is a resection at the left margin of the common bile duct, removing most of the head, uncus, body, and tail of the pancreas; and 98% pancreatectomy is a resection of most of the pancreas, leaving only the pancreatic tissues surrounding the pancreaticoduodenal arteries (100).
• After near total (98%) pancreatectomy, euglycemia is achieved in only 7-50% of patients, while hypoglycemia remains in 17-59% of patients and hyperglycemia in 17-100%. Postsurgical glycemic control after near total/subtotal pancreatectomy is difficult to predict before surgery (18, (100) (101) (102) . Furthermore, it has been reported that, after prolonged follow up until puberty, 100% of the patients developed diabetes mellitus with 91% of them being insulin dependent (18). • Lord et al. reviewed 97 children with diffuse CHI who underwent near-total pancreatectomy (median extent: 98%), and found that only 23% of them were discharged with euglycemia, 51% (40 cases) required additional medical treatment for residual hypoglycemia, and 36% (35 cases) required treatment for hyperglycemia at discharge (103).
• Research on patients who underwent 95% pancreatectomy, found that 60% had residual hypoglycemia, which was comparable to the cases of 98% pancreatectomy. After a long interval between 7.3 and 13 yr of age, diabetes mellitus developed in 45-100% of patients (17, (104) (105) (106) ).
• A study on 45 patients who underwent 95% pancreatectomy found that 22 (49%) developed hyperglycemia requiring insulin. Ten of these required insulin immediately after surgery, although insulin was only transiently required in 4 patients. The proportion of patients requiring insulin was 77% after 7 yr and 96% after 11 yr (17).
• A meta-analysis of 422 cases from 12 reports between 1997 and 2009 identified 103 cases of diffuse CHI. Of these, 36% had residual hypoglycemia and 31% had hyperglycemia or diabetes mellitus following 80-98% pancreatectomy (107).
• A report from a single-center experience involving 250 cases after pancreatectomy of diffuse CHI, found that 50% of patients had residual hypoglycemia, 25% required insulin for hyperglycemia, and only 25% had euglycemia. However, glycemic control was easier following pancreatectomy (108).
• In a further report on 10 cases of diffuse CHI, all patients who underwent 95% pancreatectomy developed diabetes mellitus, three of them immediately following surgery and seven after a median of 8 yr (106).
• The most common postsurgical complication was bleeding. Bile ducts damage was more common after 95% pancreatectomy or redo-operation than after subtotal pancreatectomy <80% (11.9-22.2%) (109).
• After 95% pancreatectomy, abnormalities of exocrine function were common, with abnormalities of fecal elastase I in 72% of patients and symptomatic exocrine insufficiency in 49% (17).
• For patients resistant to medical treatment, > 95% pancreatectomy is useful for the control of hypoglycemia. However, extremely high incidence of postsurgical diabetes mellitus has also been reported. Considering the self-remitting nature of CHI, some investigators recommend avoiding > 95% pancreatectomy as far as possible. Furthermore, the optimal extent of resection has not been established; therefore, no recommendation can be made at the moment. • A focal lesion in the head of the pancreas should be completely removed either by pancreas head resection or by enucleation. These procedures allow optimal control of euglycemia without the need for intravenous glucose, and can be achieved without major postsurgical complications (25, 110, 111 ).
• The majority of the focal lesions have a diameter of < 1 cm and 50% of them are located in the head of the pancreas (25, 107).
• Pre-and intra-operative localization of a focal lesion is extremely important (108) . A focal lesion may have tentacles of diseased tissue, extending to form a large lesion. Therefore, intraoperative pathological evaluations are important to determine the extent of resection. Laparoscopic surgery is not recommended for a focal lesion in the head of the pancreas (112).
• In patients with diazoxide-unresponsive CHI and a paternally-inherited monoallelic mutation in one of the K ATP channel genes, detected by molecular analysis, the possibility of a focal lesion should be considered and an 18 F-DOPA PET scan should be performed.
• Previously, arterial stimulation venous sampling (ASVS) was performed to detect a focal lesion (113).
• However, 18 F-DOPA PET/CT scan is superior to ASVS and is the first choice for the detection of a focal lesion (114, 115) . The pooled accuracy of 18 F-DOPA PET scan by meta-analysis has been reported as 82% (22) . Furthermore, according to a standardized protocol of 18 F-DOPA PET/CT published in 2005, a focal lesion could be accurately localized with a sensitivity of 94% and a specificity of 100% (84) . Conversely, it has been reported that focal lesions in the head of the pancreas could be accurately diagnosed by 18 • In many patients with CHI, even those with persistent CHI, hypoglycemia gradually resolves and patients no longer require medication (7, 10, 52) . However, remission may require several months to several years, and some patients still require treatment after adulthood. The decision to discontinue medical treatment is a 2-step process, considering (1) whether medication could be discontinued and (2) whether nutritional therapy could be discontinued. It is important to carefully assess whether each therapy can be discontinued without increasing episodes of hypoglycemia.
• Some investigators propose that diazoxide could be discontinued when the dosage is below 5 mg/kg/d (117) . However, we are aware of patients who developed hypoglycemia upon withdrawal of diazoxide when the dosage was decreased to 2 mg/kg/d. We therefore set the dosage of diazoxide at 1 mg/kg/d as the threshold to consider discontinuation of therapy. As in the majority of cases, relapse of hypoglycemia occurs within 7 d of diazoxide withdrawal (118) 
VII Future Perspectives
Novel therapies for CHI include long-acting octreotides (119), GLP1 receptor antagonists (120), Lanreotide (121, 122) , insulin receptor antagonists (123) , Pasireotide (124), ω3 unsaturated fatty acids (125) , or mTOR inhibitors (126). In addition, water soluble glucagon is under development. These guidelines may require further revision in the near future to incorporate these advances in the treatment.
E. Revision
These guidelines will be revised within 5 years of release. Members of the revision committee will be appointed by the board of directors of the Japanese Society for Pediatric Endocrinology and the Japanese Society of Pediatric Surgeons. The revision committee could include other multidisciplinary health care professionals from outside the Societies. When a novel finding emerges that could affect the content of these guidelines, minor-revisions may be performed, with the approval of the board of directors of both Societies. Vol.26 / No.3 
